Isabelle Scheer-Senyarich

Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

P. Petrow, N. Basset-Seguin, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phenotypic and Functional Characteristics of Blood Natural Killer Cells from Melanoma Patients at Different Clinical Stages

I. Cremer, M. Messaoudene, M. Avril, 2013, PloS one.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

P. Petrow, M. Boubaya, J. Grob, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN.

P. Petrow, M. Boubaya, J. Grob, 2019, Journal of Clinical Oncology.

CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC).

M. Boubaya, O. Schischmanoff, V. Lévy, 2017 .

Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.

N. Farman, F. Jaisser, P. Arnaud, 2015, The Journal of investigative dermatology.

Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.

N. Farman, F. Jaisser, P. Arnaud, 2015, The Journal of investigative dermatology.